Fig 1.
Cohort selection flow diagram.
Flow Diagram of patient sampling strategy of hospitalized COVID-19 patients in Hackensack Meridian Health network. *Convenience sampling was performed when assigning patients to our data team, and sampling bias is possible. 3325 of the 3438 (97%) available records were abstracted. **Follow-up until final study cut-off date of May 5, 2020. *** 53 patients who received toci did not have sufficient data (date of administration) to analyze Tocilizumab (toci); Hydroxychloroquine (HCQ).
Table 1.
Unadjusted baseline characteristics of hospitalized COVID-19 patients.
Fig 2.
Unadjusted association of treatment with hydroxychloroquine on overall survival among hospitalized COVID-19 patients.
Unadjusted Kaplan-Meier estimates of survival by treatment allocation to hydroxychloroquine (HCQ), azithromycin (AZI), both, or neither. Patients at risk at admission, day 10, day 20, and day 30 are shown. Patients still alive and in the hospital were censored as of May 5, 2020. Patients who had been discharged from the hospital were censored as of day 36 following hospital admission. 30-day mortality rates are shown for each treatment.
Table 2.
Propensity-score adjusted hazard ratios, confidence intervals.
Fig 3.
Unadjusted association of treatment with tocilizumab on overall survival among hospitalized ICU COVID-19 patients.
Unadjusted Kaplan-Meier estimates of survival by treatment allocation to tocilizumab (toci) or no toci. Patients at risk at admission, day 10, day 20, and day 30 are shown. Patients still alive and in the hospital were censored as of May 5, 2020. Patients who had been discharged from the hospital were censored as of day 36 following hospital admission. 30-day unadjusted mortality with and without tocilizumab is 46% versus 56%.
Table 3.
Unadjusted baseline characteristics of evaluable ICU patients receiving tocilizumab.